Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179881 · ClinicalTrials.gov registry record · Phase 2
Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
A Phase 2 study of Brain Stem Neoplasms, Primary and Neoplasms, Brain Stem, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 6
- Study locations
NCT00179881: Completed Phase 2 study of Brain Stem Neoplasms, Primary and Neoplasms, Brain Stem, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
NCT00179881 is a Phase 2 study of Brain Stem Neoplasms, Primary and Neoplasms, Brain Stem that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00179881, a Phase 2 study of Brain Stem Neoplasms, Primary and Neoplasms, Brain Stem, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 6
- Study locations
Study Summary
Treatment on this study combines two drugs: Thalomid™ (thalidomide) and carboplatin. Thalidomide has been available for many years and has been used to treat many different illnesses. Carboplatin is an effective medicine in killing cancer cells. Thalidomide works by blocking angiogenesis (the process of new blood vessel formation). If a tumor does not have blood vessels providing oxygen and nutrients, it will not be able to grow. This research will look at how combining the effects of thalidomide (preventing tumor growth) with the tumor killing effect of carboplatin effects the long-term outlook for patients with these tumors. This study will try to find out how well Thalomid™ and carboplatin combined with radiation therapy works in treating children newly diagnosed with brain stem glioma. This study will look at how well Thalomid ™ and carboplatin work in patients with recurrent brain stem glioma. This study will also look at any side effects of these treatments.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Thalomid
- PROCEDURE External Beam Radiation Therapy
Study Locations (6)
Minnesota
- Children's Hospitals and Clinics - Minneapolis
- Children's Hospitals and Clinics - Saint Paul
Arizona
- Phoenix Children's Hospital - Phoenix
Illinois
- Children's Memorial Hospital - Chicago
Missouri
- Washington University Medical Center - St Louis
Ohio
- Children's Medical Center - Dayton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 1999-12 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
What the finished NCT00179881 record still lists
NCT00179881 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Brain Stem Neoplasms, Primary appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT00179881 lists 6 locations in 5 states (Minnesota, Arizona, Illinois).
Frequently Asked Questions
What is clinical trial NCT00179881 about?
NCT00179881 is a clinical study titled "Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma". Treatment on this study combines two drugs: Thalomid™ (thalidomide) and carboplatin. Thalidomide has been available for many years and has been used to treat many different illnesses. Carboplatin is an effective medicine in killing cancer cells. Thalidomide works by blocking angiogenesis (the proces...
What is the current status of trial NCT00179881?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 1999-12. Estimated completion is 2007-04.
What conditions does trial NCT00179881 study?
This clinical trial studies the following conditions: Brain Stem Neoplasms, Primary, Neoplasms, Brain Stem.
What interventions are being tested in trial NCT00179881?
The interventions under investigation include: Carboplatin (DRUG), Thalomid (DRUG), External Beam Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00179881?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00179881 being conducted?
This trial has 6 study locations across Arizona, Illinois, Minnesota, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00179881's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia